For the quarter ending 2026-03-31, RNAC made $78K in revenue. -$39,189K in net income. Net profit margin of -50242.31%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 78 | 947 | 452 | 298 |
| Research and development | 19,463 | 14,689 | 13,802 | 14,869 |
| General and administrative | 7,114 | 8,197 | 7,716 | 7,240 |
| Impairment of indefinite-lived intangible and long-lived assets | - | 56,700 | - | - |
| Total operating expenses | 26,577 | 79,586 | 21,518 | 22,109 |
| Operating loss | -26,499 | -78,639 | -21,066 | -21,811 |
| Interest income | - | - | 1,548 | 1,748 |
| Loss on change in fair value of forward contract liabilities | - | 0* | 0 | 0 |
| Interest income | 1,026 | 1,645* | - | - |
| Gain on change in fair value of warrant liabilities | -94 | -707 | -516 | -654 |
| (loss) gain on change in fair value of contingent value right liability | 13,800 | 23,100 | 16,900 | -35,300 |
| Other expense, net | -3 | 4,513* | 0 | -5 |
| Total other (expense) income, net | -12,683 | -16,235 | - | - |
| Loss before income taxes | - | -94,874* | - | - |
| Income tax benefit (expense) | - | -2,298* | - | - |
| Net loss | -39,182 | -92,576 | -35,902 | 15,886 |
| Foreign currency translation adjustment | -7 | 11 | -10 | 12 |
| Total comprehensive loss | -39,189 | -92,565 | -35,912 | 15,898 |
| Basic EPS | -1.46 | -3.559 | -1.38 | 0.51 |
| Diluted EPS | -1.46 | -3.624 | -1.38 | 0.5 |
| Basic Average Shares | 26,855,158 | 26,007,512 | 26,002,892 | 25,980,262 |
| Diluted Average Shares | 26,855,158 | 25,540,523 | 26,002,892 | 26,447,251 |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)